Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior

摘要: Purpose: The distribution of pretreatment and posttreatment prostate specific antigen (PSA) doubling times (PSADT) varies widely. This report examines the PSADT as an independent predictor biochemical freedom from disease (bNED) describes clinical utility PSADT. Methods Materials: Ninety-nine patients with T1-3 NX, M-0 cancer treated between February 1989 November 1993 have PSADTs calculated three more PSA levels. Biochemical disease-free survival (failure is ≥ 1.5 ngm/ml rising) evaluated by multivariate analysis common prognostic indicators PSADT. Results: Prostate-specific antigen, time a significant along radiation dose. Patients od < 12 months show 50% failure 18 months, while those that not increasing only 3% at 3 years. Conclusions: bNED outcome in cancer. aggressive should be considered for multimodal therapy. Slow (≥ 5 years) observed 57% patients, this end point may decision to observe rather than treat. After treatment failure, used determine which do need immediate androgen deprivation.